Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
From the Editor

Autoimmune brain disease: Think before testing

Brian F. Mandell, MD, PhD
Cleveland Clinic Journal of Medicine August 2021, 88 (8) 420-421; DOI: https://doi.org/10.3949/ccjm.88b.08021
Brian F. Mandell
Roles: Editor in Chief
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Find this author on Cleveland Clinic
  • Article
  • Info & Metrics
  • PDF
Loading

Embedded Image

As a rheumatologist, I have the opportunity to see many patients in consultation for the evaluation of complex and often difficult-to-define symptoms. The buzzword referral diagnosis is frequently “autoimmune.” In 2021, autoimmune is seemingly the evil humor or miasma of centuries past revisited, with the added distinction that there are laboratory tests that can be ordered that, if positive, seem to provide superficial evidence for the validity of this diagnosis.

The problem is that many immune serologic tests are not specific for any defined clinical diagnosis and thus should not be used to drive therapeutic decisions. However, such testing may create significant angst and expectations in patients and their families. Indiscriminate testing often begets additional testing and specialty referrals. Obtaining an antinuclear antibody test in a patient with fatigue, brain fog, and diffuse pain as the primary symptoms—but with no diagnostically relevant basic laboratory testing or physical examination abnormalities—is invariably unhelpful to the patient1 and, if positive, is often emotionally and financially costly.

Many of the final diagnoses, even if these autoimmune tests are positive, are not autoimmune in nature. This is because many of these serologies have little specificity (poor positive predictive value). Within this bucket of autoimmune tests are rheumatoid factor and the antinuclear antibody test and related antibody tests (anti-SSA, anti-RNP, and even to some extent anti-DNA). In a second bucket are tests that detect antibodies pathogenically linked to specific clinical syndromes, such as anti-glomerular basement membrane antibody, linked to the glomerular basement membrane subset of Goodpasture syndrome; anti-AQP4, linked to neuromyelitis optica; and anti-acetylcholine receptor, linked to myasthenia gravis. These tests are of course also susceptible to misinterpretation (false positives) if ordered indiscriminately without the appropriate clinical context. But these antibodies do have a strong pathogenic link to specific clinical disorders.

Since truly pathogenic antibodies have been identified that cause or drive heretofore unexplained complex clinical syndromes, it is no surprise that research has moved toward trying to identify additional ones. There is hope in the scientific and patient communities that such identification can result in new approaches to molecular therapy.

The 2012 autobiography by Susannah Cahalan, Brain on Fire: My Month of Madness, and the movie based on it relate the intense story of a young woman ultimately diagnosed with anti-N-methyl-d-aspartate (NMDA) receptor-associated autoimmune encephalitis—a disorder with associated antibody that has a strong pathogenic link to clinical disease. Without knowledge of the antibody to the NMDA receptor, this disorder might still remain a mystery to diagnose, and a huger challenge to treat. In this issue of the Journal, Abbatemarco et al present a practical discussion of recognizing and managing patients with this and other forms of autoimmune encephalitis.

As a nonneurologist, I find these syndromes striking for several reasons. There is a biology that ultimately will be teased apart to explain how these specific antibodies sort to specific syndromes. It is fairly easy to conceptualize how antibodies binding to surface receptors can disrupt the function of the cells bearing those receptors and their associated intercellular networks. Perhaps careful clinical characterization of these syndromes will provide insight into further understanding of complex brain networking, specifically, what is the connection between characteristic focal facial seizures and encephalitis, or encephalomyelitis and sensory neuropathies? But we still have a way to go in understanding how antibodies recognizing intracellular targets are pathogenic, and why there are links between these syndromes and certain malignancies.

From the literature, I am not quite sure of the predictive value of these antibodies. For me, a takeaway from the article by Abbatemarco et al is that clinical suspicion for these rare syndromes should come first, followed by appropriate referral and subsequent thoughtful consideration for ordering these antibody panels from both blood and cerebrospinal fluid.

  • Copyright © 2021 The Cleveland Clinic Foundation. All Rights Reserved.

References

  1. ↵
    1. Nashi RA,
    2. Shmerling RH
    . Antinuclear antibody testing for the diagnosis of systemic lupus erythematosus. Med Clin M Am 2021; 105:387–396. doi:10.1016/j.mcna.2020.10.003
    OpenUrlCrossRef
PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 88 (8)
Cleveland Clinic Journal of Medicine
Vol. 88, Issue 8
1 Aug 2021
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Autoimmune brain disease: Think before testing
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Autoimmune brain disease: Think before testing
Brian F. Mandell
Cleveland Clinic Journal of Medicine Aug 2021, 88 (8) 420-421; DOI: 10.3949/ccjm.88b.08021

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Autoimmune brain disease: Think before testing
Brian F. Mandell
Cleveland Clinic Journal of Medicine Aug 2021, 88 (8) 420-421; DOI: 10.3949/ccjm.88b.08021
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • References
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • The gift of lasting immunity
  • Psychedelics in the medical toolbox?
  • All sulfa drugs are not created equal
Show more From the Editor

Similar Articles

Subjects

  • Drug Therapy
  • Endocrinology
  • Neurology
  • Rheumatology

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire